Tonix Pharmaceuticals Holding Corp. (TNXP) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
TNXP Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at a price-to-earnings ratio of -0.1x, with a stock price of $13.62 and trailing twelve-month earnings per share of $-11.12.
Compared to the Healthcare sector median P/E of 22.3x, TNXP trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TNXP trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TNXP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TNXP P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $5B | 62.3 | - | -33% | |
| $930M | 147.8 | - | +107% | |
| $2B | 68.8 | - | +194% | |
| $5B | 8.3 | - | +264% | |
| $4B | 9.9 | - | +68% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See TNXP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNXP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNXP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTNXP — Frequently Asked Questions
Quick answers to the most common questions about buying TNXP stock.
Is TNXP stock overvalued or undervalued?
TNXP current P/E: -0.1x. 5-year average P/E: N/A. Percentile: N/A.
How does TNXP's valuation compare to peers?
Tonix Pharmaceuticals Holding Corp. P/E of -0.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TNXP's PEG ratio?
TNXP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.